Developer docs
API playgroundTry for free, no card

Search company profiles

Vicarious Surgical

Full company profile

uuid000021s

Namestring
Vicarious Surgical
Legal namestring
Vicarious Surgical Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Vicarious Surgical Inc. is a Waltham, Massachusetts-based robotics company founded in 2014 that is developing a single-port surgical robotics platform for minimally invasive abdominal surgery. The system comprises two main hardware components—a Patient Cart that connects with the patient and a Surgeon Console where the surgeon controls robotic instruments via hand controllers—and is differentiated by a 1.5 cm incision (vs. multi-port conventional robotic surgery), two robotic arms with 13 degrees of freedom each, 28 sensors per arm designed to replicate human upper-body motion from shoulders to wrists, and immersive 3D stereoscopic visualization in which all robotic motion occurs inside the patient to eliminate external collisions. The company received FDA Breakthrough Device Designation and is targeting design freeze by end of 2026 ahead of regulatory submission.

Vicarious Surgical is pre-revenue and has not yet obtained FDA clearance for commercial sale. Its intended revenue model combines capital equipment sales of the surgical system to hospitals and ambulatory surgical centers with recurring revenue from proprietary disposable instruments (including a dedicated suite for ventral hernia repair covering IPOM and rTAPP approaches) and service contracts. Go-to-market is consultative enterprise field sales targeting large hospital systems and academic medical centers, with a clinical collaboration signed in May 2025 with UMass Memorial Medical Center (an 826-bed academic medical center) serving as flagship validation site for workflow, surgeon education, and downstream adoption.

The company went public in September 2021 via a SPAC business combination with D8 Holdings Corp. (NYSE: RBOT), raising approximately $220M, followed by a ~$45M underwritten public offering in August 2023 and a ~$5.9M registered direct offering in October 2025. Under new CEO Stephen From (appointed August 2025), the company has executed a significant operational reset: 2026 cash burn guidance was reduced to approximately $19M from approximately $50M in mid-2025, Q1 2026 operating expenses fell 52% year-over-year to $7.5M, and a strategic software execution partnership with a global digital engineering firm was signed in December 2025 to accelerate development. However, the company received an NYSE delisting notice in March 2026 after market capitalization fell below the $15M minimum, with shares now trading on OTCQB pending a Nasdaq relisting application and reverse stock split. Cash position as of March 31, 2026 was $1.4M in cash and $2.3M in short-term investments, with management stating runway only through Q2 2026 pending additional capital raises.

Short descriptiontext

Vicarious Surgical is a pre-revenue robotics company developing a single-port surgical system for minimally invasive abdominal surgery, featuring miniaturized robotic arms with human-like motion through a 1.5 cm incision, targeting hospitals and ambulatory surgical centers pending FDA clearance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
surgical robotics systems, minimally invasive surgery, robotic-assisted surgery, single-port surgical robot, medical device manufacturing
Industry5 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Robotics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Surgical Robotics System Sales
TypeHardware Sales
Description

Pre-revenue company developing a single-port surgical robot for minimally invasive abdominal surgery. The company has not yet commercialized its product and has not received FDA clearance. Revenue model will likely involve capital equipment sales to hospitals and ambulatory surgical centers, potentially with recurring revenue from proprietary instruments and service contracts.

vicarioussurgical.com
2Proprietary Instruments and Consumables
TypeHardware Sales
Description

The system uses disposable surgical instruments that would generate recurring revenue per procedure. The company is developing its integrated instrument suite including monopolar scissors for ventral hernia repair procedures.

vicarioussurgical.com
3Service and Support Contracts
TypeProfessional Services
Description

Expected to include installation, training, maintenance, and technical support services associated with capital equipment placement in hospitals and surgical centers.

vicarioussurgical.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vicarious Surgical develops a single-port robotic surgical system designed for minimally invasive abdominal surgery. The system features two robotic arms with 28 sensors each and 13 degrees of freedom, entering the patient through a 1.5 cm incision and controlled from a surgeon console with immersive 3D visualization and hand controllers. The product has not yet received FDA clearance and is not yet commercialized; the company is targeting ventral hernia repair as its initial procedure focus.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Incision size as small as 1.2 cm (1.5 cm target with new disposables)
+3 more records
Product overview1 text field

Vicarious Surgical offers a single-port surgical robotics platform consisting of the Vicarious Surgical System as the core product. The system comprises two main components: the Patient Cart (patient-side interface enabling robotic entry through a single incision) and the Surgeon Console (where surgeons control instruments and camera using hand controllers and proprietary software). The company is developing a dedicated Surgical Instrument Suite for ventral hernia repair, including monopolar scissors and other core instruments. All robotic motion occurs inside the patient through a 1.5 cm incision, with the system designed to replicate a surgeon's natural upper body movements from shoulders to elbows to wrists.

Product and service2 records
1Vicarious Surgical System
CategorySurgical Robotics Platform
Description

A single-port robotic surgery platform designed for minimally invasive abdominal surgery, comprising a Patient Cart (patient-side interface) and a Surgeon Console with proprietary software and hand controllers. Targets acute care hospitals and ambulatory surgical centers performing abdominal procedures.

2Surgical Instrument Suite for Ventral Hernia Repair
CategorySurgical Instruments / Consumables
Description

Integrated surgical instrument suite including monopolar scissors for energy delivery and cauterization, designed specifically for ventral hernia repair procedures (IPOM and rTAPP approaches) using the Vicarious Surgical System.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Global Digital Engineering and Software Development Services Firm (unnamed)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-12-29
Description

Strategic software execution partnership to support development of the Vicarious Surgical robotic system. The external partner assumes responsibility for significant software development activities including control systems, visualization, and key workflow components. The partnership aims to increase development velocity, enhance milestone predictability, and reduce operating expenses as part of the company's operational transformation. Partner's global footprint and mature engineering processes are expected to support progress toward design freeze.

vicarioussurgical.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-12
Description

Strategic collaboration signed in May 2025 to support adoption and utilization of Vicarious Surgical's robotic system. Focus areas include streamlining inventory management and sterilization protocols, standardization of pre-procedure processes and post-procedure care, case observation for surgeons, and system testing. The collaboration leverages UMass Memorial's expertise as a leading academic medical center with 826 beds to refine and validate best practices in perioperative workflows.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

The dominant manufacturer of the da Vinci surgical robotics platform for minimally invasive abdominal and pelvic procedures. Intuitive is Vicarious's primary direct competitor; Vicarious must demonstrate clinical and economic advantages sufficient to justify a second platform in da Vinci-equipped hospitals.

TypeBroad incumbent
Description

Medtronic's Hugo RAS system is a multi-port soft-tissue surgical robotics platform competing directly in the same abdominal minimally invasive surgery market. As a diversified medtech incumbent, Medtronic brings scale, capital, and a global hospital salesforce that Vicarious must contend with in commercialization.

TypeDirect peer
Description

UK-based developer of the Versius surgical robotics system, a modular multi-port soft-tissue robot targeting laparoscopic abdominal procedures. Versius is the most analogous emerging single-specialty robotics competitor to Vicarious in Europe and select global markets.

TypeDirect peer
Description

Developer of the Senhance digital laparoscopy platform, positioned as a lower-cost alternative in soft-tissue minimally invasive surgery. Asensus is a small public peer with a similar capital-constrained commercialization trajectory and a directly overlapping abdominal surgery use case.

TypeEmerging player
Description

French-American early-stage company developing a soft-tissue surgical robotics assistant for laparoscopic abdominal procedures. Moon Surgical represents a comparable single-port-adjacent emerging player competing for similar hospital and ASC customers.

TypeBroad incumbent
Description

J&J's Ottava general surgery robotics platform targets the same minimally invasive abdominal market as Vicarious, leveraging J&J's surgical instruments, Ethicon franchise, and global hospital relationships. J&J is also a relevant potential strategic acquirer given its existing investment ecosystem around Vicarious.

TypeOthers
Description

While Stryker's Mako platform focuses on orthopedic procedures (knee, hip, spine) rather than soft-tissue abdominal surgery, Stryker is a relevant broader competitor in hospital surgical robotics and a potential strategic acquirer for Vicarious given its pattern of tuck-in medtech M&A.

TypeEmerging player
Description

Boston-area developer of AI-driven intraoperative visualization and software for existing laparoscopic and robotic platforms. Activ is an emerging player addressing adjacent surgical decision-support and imaging challenges that complement, but do not directly replicate, Vicarious's robotic platform play.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vicarious Surgical

Surgical Roboticsvicarioussurgical.com

Vicarious Surgical is a pre-revenue robotics company developing a single-port surgical system for minimally invasive abdominal surgery, featuring miniaturized robotic arms with human-like motion through a 1.5 cm incision, targeting hospitals and ambulatory surgical centers pending FDA clearance.

What Vicarious Surgical does

Vicarious Surgical Inc. is a Waltham, Massachusetts-based robotics company founded in 2014 that is developing a single-port surgical robotics platform for minimally invasive abdominal surgery. The system comprises two main hardware components—a Patient Cart that connects with the patient and a Surgeon Console where the surgeon controls robotic instruments via hand controllers—and is differentiated by a 1.5 cm incision (vs. multi-port conventional robotic surgery), two robotic arms with 13 degrees of freedom each, 28 sensors per arm designed to replicate human upper-body motion from shoulders to wrists, and immersive 3D stereoscopic visualization in which all robotic motion occurs inside the patient to eliminate external collisions. The company received FDA Breakthrough Device Designation and is targeting design freeze by end of 2026 ahead of regulatory submission.

Vicarious Surgical is pre-revenue and has not yet obtained FDA clearance for commercial sale. Its intended revenue model combines capital equipment sales of the surgical system to hospitals and ambulatory surgical centers with recurring revenue from proprietary disposable instruments (including a dedicated suite for ventral hernia repair covering IPOM and rTAPP approaches) and service contracts. Go-to-market is consultative enterprise field sales targeting large hospital systems and academic medical centers, with a clinical collaboration signed in May 2025 with UMass Memorial Medical Center (an 826-bed academic medical center) serving as flagship validation site for workflow, surgeon education, and downstream adoption.

The company went public in September 2021 via a SPAC business combination with D8 Holdings Corp. (NYSE: RBOT), raising approximately $220M, followed by a ~$45M underwritten public offering in August 2023 and a ~$5.9M registered direct offering in October 2025. Under new CEO Stephen From (appointed August 2025), the company has executed a significant operational reset: 2026 cash burn guidance was reduced to approximately $19M from approximately $50M in mid-2025, Q1 2026 operating expenses fell 52% year-over-year to $7.5M, and a strategic software execution partnership with a global digital engineering firm was signed in December 2025 to accelerate development. However, the company received an NYSE delisting notice in March 2026 after market capitalization fell below the $15M minimum, with shares now trading on OTCQB pending a Nasdaq relisting application and reverse stock split. Cash position as of March 31, 2026 was $1.4M in cash and $2.3M in short-term investments, with management stating runway only through Q2 2026 pending additional capital raises.

Vicarious Surgical firmographics

Firmographics
Name
Vicarious Surgical
Legal name
Vicarious Surgical Inc.
Website
https://vicarioussurgical.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Vicarious Surgical is a pre-revenue robotics company developing a single-port surgical system for minimally invasive abdominal surgery, featuring miniaturized robotic arms with human-like motion through a 1.5 cm incision, targeting hospitals and ambulatory surgical centers pending FDA clearance.
Ownership category
akta.pro rank

Vicarious Surgical industry classification

Industry
Product category
Surgical Robotics
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Surgical robotics systems
  • Minimally invasive surgery
  • Robotic-assisted surgery
  • Single-port surgical robot
  • Medical device manufacturing

Where Vicarious Surgical is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vicarious Surgical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Surgical Robotics System Sales: Pre-revenue company developing a single-port surgical robot for minimally invasive abdominal surgery. The company has not yet commercialized its product and has not received FDA clearance. Revenue model will likely involve capital equipment sales to hospitals and ambulatory surgical centers, potentially with recurring revenue from proprietary instruments and service contracts.
  2. Proprietary Instruments and Consumables: The system uses disposable surgical instruments that would generate recurring revenue per procedure. The company is developing its integrated instrument suite including monopolar scissors for ventral hernia repair procedures.
  3. Service and Support Contracts: Expected to include installation, training, maintenance, and technical support services associated with capital equipment placement in hospitals and surgical centers.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Vicarious Surgical product offering

Product offering

Core offering

Vicarious Surgical develops a single-port robotic surgical system designed for minimally invasive abdominal surgery. The system features two robotic arms with 28 sensors each and 13 degrees of freedom, entering the patient through a 1.5 cm incision and controlled from a surgeon console with immersive 3D visualization and hand controllers. The product has not yet received FDA clearance and is not yet commercialized; the company is targeting ventral hernia repair as its initial procedure focus.

Product overview

Vicarious Surgical offers a single-port surgical robotics platform consisting of the Vicarious Surgical System as the core product. The system comprises two main components: the Patient Cart (patient-side interface enabling robotic entry through a single incision) and the Surgeon Console (where surgeons control instruments and camera using hand controllers and proprietary software). The company is developing a dedicated Surgical Instrument Suite for ventral hernia repair, including monopolar scissors and other core instruments. All robotic motion occurs inside the patient through a 1.5 cm incision, with the system designed to replicate a surgeon's natural upper body movements from shoulders to elbows to wrists.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vicarious Surgical System A single-port robotic surgery platform designed for minimally invasive abdominal surgery, comprising a Patient Cart (patient-side interface) and a Surgeon Console with proprietary software and hand controllers. Targets acute care hospitals and ambulatory surgical centers performing abdominal procedures.
  • Surgical Instrument Suite for Ventral Hernia Repair Integrated surgical instrument suite including monopolar scissors for energy delivery and cauterization, designed specifically for ventral hernia repair procedures (IPOM and rTAPP approaches) using the Vicarious Surgical System.

Quantifiable outcome

  • Incision size as small as 1.2 cm (1.5 cm target with new disposables)
  • +3 more outcomes

Companies that use Vicarious Surgical

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Vicarious Surgical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Vicarious Surgical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Global Digital Engineering and Software Development Services Firm (unnamed)coreImplementation/ SI/ Consulting Partner · 29 December 2025Strategic software execution partnership to support development of the Vicarious Surgical robotic system. The external partner assumes responsibility for significant software development activities including control systems, visualization, and key workflow components. The partnership aims to increase development velocity, enhance milestone predictability, and reduce operating expenses as part of the company's operational transformation. Partner's global footprint and mature engineering processes are expected to support progress toward design freeze.
  • UMass Memorial Medical CentercoreStrategic or Co-development Partner · 12 May 2025Strategic collaboration signed in May 2025 to support adoption and utilization of Vicarious Surgical's robotic system. Focus areas include streamlining inventory management and sterilization protocols, standardization of pre-procedure processes and post-procedure care, case observation for surgeons, and system testing. The collaboration leverages UMass Memorial's expertise as a leading academic medical center with 826 beds to refine and validate best practices in perioperative workflows.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Vicarious Surgical competitors and assessment

Company assessment

Direct peers

  • Intuitive Surgical: The dominant manufacturer of the da Vinci surgical robotics platform for minimally invasive abdominal and pelvic procedures. Intuitive is Vicarious's primary direct competitor; Vicarious must demonstrate clinical and economic advantages sufficient to justify a second platform in da Vinci-equipped hospitals.
  • CMR Surgical: UK-based developer of the Versius surgical robotics system, a modular multi-port soft-tissue robot targeting laparoscopic abdominal procedures. Versius is the most analogous emerging single-specialty robotics competitor to Vicarious in Europe and select global markets.
  • Asensus Surgical: Developer of the Senhance digital laparoscopy platform, positioned as a lower-cost alternative in soft-tissue minimally invasive surgery. Asensus is a small public peer with a similar capital-constrained commercialization trajectory and a directly overlapping abdominal surgery use case.

Broad incumbents

  • Medtronic (Hugo Robotic-Assisted Surgery): Medtronic's Hugo RAS system is a multi-port soft-tissue surgical robotics platform competing directly in the same abdominal minimally invasive surgery market. As a diversified medtech incumbent, Medtronic brings scale, capital, and a global hospital salesforce that Vicarious must contend with in commercialization.
  • Johnson & Johnson (Ottava): J&J's Ottava general surgery robotics platform targets the same minimally invasive abdominal market as Vicarious, leveraging J&J's surgical instruments, Ethicon franchise, and global hospital relationships. J&J is also a relevant potential strategic acquirer given its existing investment ecosystem around Vicarious.

Emerging players

  • Moon Surgical: French-American early-stage company developing a soft-tissue surgical robotics assistant for laparoscopic abdominal procedures. Moon Surgical represents a comparable single-port-adjacent emerging player competing for similar hospital and ASC customers.
  • Activ Surgical: Boston-area developer of AI-driven intraoperative visualization and software for existing laparoscopic and robotic platforms. Activ is an emerging player addressing adjacent surgical decision-support and imaging challenges that complement, but do not directly replicate, Vicarious's robotic platform play.

Others

  • Stryker (Mako): While Stryker's Mako platform focuses on orthopedic procedures (knee, hip, spine) rather than soft-tissue abdominal surgery, Stryker is a relevant broader competitor in hospital surgical robotics and a potential strategic acquirer for Vicarious given its pattern of tuck-in medtech M&A.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Vicarious Surgical social profiles

Digital presence

Vicarious Surgical compliance and trust

Trust signal

Compliance1 record

Vicarious Surgical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vicarious Surgical leadership team

Management profile

Number of profiles

Profiles9 records

Vicarious Surgical funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vicarious Surgical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vicarious Surgical

What does Vicarious Surgical do?

Vicarious Surgical develops a single-port robotic surgical system designed for minimally invasive abdominal surgery. The system features two robotic arms with 28 sensors each and 13 degrees of freedom, entering the patient through a 1.5 cm incision and controlled from a surgeon console with immersive 3D visualization and hand controllers. The product has not yet received FDA clearance and is not yet commercialized; the company is targeting ventral hernia repair as its initial procedure focus.

Is Vicarious Surgical a public or private company?

Vicarious Surgical is a public company. It is classified as public and is currently operating.

When was Vicarious Surgical founded?

Vicarious Surgical was founded in 2014. It employs 11 to 50 people.

Where is Vicarious Surgical based?

Vicarious Surgical is headquartered in Waltham, United States, in the North America region.

How does Vicarious Surgical make money?

Three revenue lines are on record. Surgical Robotics System Sales are the primary driver. The others are proprietary Instruments and Consumables and service and Support Contracts.

Who are Vicarious Surgical's main competitors?

Direct peers on record are Intuitive Surgical, CMR Surgical and Asensus Surgical. Broad incumbents are Medtronic (Hugo Robotic-Assisted Surgery) and Johnson & Johnson (Ottava). Emerging players are Moon Surgical and Activ Surgical. Stryker (Mako) is listed as an others.

Does Vicarious Surgical have an API?

No public API is recorded for Vicarious Surgical.

What industry is Vicarious Surgical in?

Vicarious Surgical's product category is Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HDAAAIAC, Healthcare & Assistive Robotics. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PedailyThe surgical robot invested by Gates went bankrupt, but Chinese counterparts have started making profits.Vicarious Surgical, a US surgical robot company backed by Bill Gates, dissolved and liquidated in July 2026 after 12 years without FDA approval or clinical trials. Chinese surgical robot firms, such as Weichuang and Shurui, reported positive profit forecasts and rising revenue, while the industry now focuses on utilization rates and consumable renewals.WebProNewsRobotics Hits Its Juicero Moment: Overhyped Kitchen Gadgets and Failed Surgical VenturesThe robotics industry is experiencing a wave of overhyped, overpriced consumer gadgets mirroring the Juicero collapse, with multiple startups raising hundreds of millions to build products that fail to justify their price tags or solve problems consumers handle cheaply. Vicarious Surgical, which raised over $425 million to develop a surgical robot challenging Intuitive Surgical, collapsed in July 2026 after shareholders voted to dissolve the company due to failure to secure regulatory clearance and rapid cash burn. Other examples include Cheffy's $400 E.G.O.R. egg-cooking robot, Weave's $8,000 laundry-folding machine, and 1X's Neo humanoid robot documented struggling with basic tasks like opening refrigerators, all underscoring that the robotics sector remains unable to deliver reliable real-world dexterity at viable economics.MassDeviceSRS 2026 recap: The biggest surgical robot stories of the last weekThe Society of Robotic Surgery Annual Meeting (SRS 2026) in Hollywood, Florida showcased multiple developments in surgical robotics, including Johnson & Johnson's long-awaited FDA de novo authorization for its Ottava surgical robot system after nearly six years of development. Medtronic unveiled its AI-native Touch Surgery Aide computing platform for robotic surgery, while Nvidia released an open-source simulation framework to help developers train surgical robots. The week also saw the shutdown and liquidation of Vicarious Surgical, which failed to reach design freeze after its 2021 SPAC merger, highlighting the volatility in the surgical robotics sector.BiggoBill Gates-Backed Surgical Robot Star Vicarious Burns Through $295.8 Million, Heads to Bankruptcy Liquidation — BigGo FinanceU.S. surgical robotics company Vicarious Surgical has entered bankruptcy liquidation after raising approximately $300 million cumulatively from investors including Bill Gates and Yahoo co-founder Jerry Yang, having gone public via SPAC in 2021 with a market cap briefly exceeding $1.2 billion. The company failed to commercialize its product, posting losses of $63 million in 2024 and $50.2 million in 2025, and by end of March held only $3.7 million in cash while still burning $7.3 million per quarter, ultimately receiving a delisting notice from NYSE before shareholders faced near-total losses. The collapse highlights broader commercialization challenges in the global embodied AI sector, where impressive technical demonstrations have failed to translate into compelling purchase rationale, with industry observers noting the sector is shifting from a capital-friendly league phase to a knockout stage where productization capability determines survival.Pedaily融资20亿,机器人公司Vicarious宣布破产American surgical robot company Vicarious Surgical has gone bankrupt after investors voted to cease operations and liquidate the company, following repeated product development delays and regulatory setbacks. Despite raising approximately $300 million (2 billion yuan) from high-profile investors including Bill Gates and Jerry Yang, and achieving a SPAC listing in 2021 with a market value exceeding $1.2 billion, the company failed to bring its products to market and received a NYSE delisting notice in March 2024 due to low stock price. The article suggests this bankruptcy reflects broader challenges in the embodied intelligence industry, where companies face difficulties commercializing radical technologies amid lengthy R&D cycles and regulatory requirements.YahooTime runs out for Vicarious SurgicalVicarious Surgical, a Waltham, Massachusetts-based surgical robotics company, is shutting down 12 years after its formation following its failure to achieve regulatory authorization for its surgical robot and inability to secure additional funding. The company, which went public via a SPAC merger with D8 Holdings in 2021 that valued it at $1.1 billion, burned through its cash reserves and was delisted from the New York Stock Exchange earlier this year. Vicarious employed 26 people as of March and intended to file for dissolution with the Delaware Secretary of State.MedTech DiveTime runs out for Vicarious SurgicalVicarious Surgical is shutting down after failing to secure regulatory authorization for its surgical robot system or find a buyer, leading to a board recommendation to dissolve the business. The company, which was valued at $1.1 billion following its 2021 SPAC merger, had previously received FDA breakthrough device designation but ultimately ran out of cash and failed to achieve commercialization. Consequently, the firm moved its shares to the over-the-counter market and is now preparing to file for dissolution in Delaware.TherobotreportVicarious Surgical officially shutting downVicarious Surgical investors voted to immediately shut down and liquidate the surgical robotics developer after the company failed to achieve a design freeze for its R&D program. The company had raised approximately $300 million, primarily through a SPAC merger in 2021, but its declining market capitalization led NYSE to place it on watchlist for potential delisting, which prevented it from raising additional capital. As of March 31, the company reported just $3.7 million in cash against $9 million in total liabilities, and an assignee will liquidate its assets—including 42,000-square-feet of office space in Waltham, Massachusetts—to settle outstanding obligations.MassDeviceRobotics developer Vicarious Surgical shuts down to liquidate assetsVicarious Surgical, a surgical robotics developer, has shut down and is liquidating its assets after investors voted to approve the closure, with the company unable to secure additional funding after being placed on a delisting watchlist by the NYSE. The company had approximately $3.7 million in cash as of March 31 against $9 million in total liabilities, having burned through roughly $300 million raised primarily through a SPAC merger in 2021 without achieving its product design freeze target. Vicarious Liquidation LLC will now sell off the company's assets, including robotics data and technology, to settle outstanding obligations, with severance payouts and full equity vesting outlined for three former executives.TherobotreportVicarious Surgical board seeks to dissolve companyVicarious Surgical's board of directors is seeking shareholder approval to dissolve and liquidate the struggling surgical robotics developer at a special meeting scheduled for July 21, with executives warning that investors are unlikely to receive any distribution from the wind-down. The company reported only $3.7 million in cash as of March 31 and $9 million in total liabilities against $12.6 million in assets, with no expectation that its cash position will sustain operations. The board said it has been unable to secure additional equity, debt, or financing and has been unsuccessful in attracting a buyer despite exploring strategic alternatives.